

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



COMPLETION OF PLACING OF NEW SHARES UNDER GENERAL MANDATE

Placing Agent



References are made to the announcement of China NT Pharma Group Company Limited (the “**Company**”) dated 1 September 2023 and the supplemental announcement of the Company dated 14 September 2023 (collectively, the “**Announcements**”), in relation to the placing of up to 475,560,000 new shares under the general mandate of the Company (the “**Placing**”). Unless otherwise stated herein, capitalized terms used herein shall have the same meanings as those defined in the Announcements.

COMPLETION OF THE PLACING

The Board is pleased to announce that all the conditions of the Placing have been fulfilled and the completion of the Placing took place on 21 September 2023. An aggregate of 263,073,000 Placing Shares have been placed by the Placing Agent to not less than six Placees at the Placing Price of HK\$0.05 per Placing Share pursuant to the terms and conditions of the Placing Agreement dated 1 September 2023 entered into between the Company and the Placing Agent.

To the best of the Directors’ knowledge, information and belief, having made all reasonable enquiries, the Placees and their ultimate beneficial owners (if applicable) are (i) independent of the Company (and the Group), its connected person(s) and their respective associate(s); and (ii) independent of and not concerted parties with any persons, other Placee(s) or Shareholders. None of the Placee(s) has become a substantial Shareholder of the Company immediately after completion of the Placing as at the date of this announcement.

UPDATE ON USE OF PROCEEDS FROM THE PLACING

The gross proceeds from the Placing amount to HK\$13,153,650 and the net proceeds (after deducting the placing commission and other related expenses and professional fees) from the Placing amount to approximately HK\$12.0 million, respectively. As disclosed in the Announcements, 50% of the net proceeds from the Placing were intended to be applied towards the business development of the Group and 50% towards the working capital of the Group to support its business operations. As the Placing Shares were not fully placed, the Company intends to adjust the use of proceeds as follows:

	Amount of net proceeds from the Placing <i>HK\$'000</i>
Business development	
For the processing fee to produce orthopaedic drugs under the pharmaceutical license	2,000
For the development of bone health products	1,500
For the capital of the research and development of Orticumab	2,900
Working capital	
Service fees for professional parties	2,500
Office rental and utilities expenses	500
Directors' emoluments and staff salaries	1,500
Other general expenses	1,100
	<hr/>
	12,000
	<hr/> <hr/>

EFFECT OF THE PLACING ON SHAREHOLDING

Set out below is the shareholding structure of the Company immediately before and upon completion of the Placing:

Name of Shareholders	(i) Immediately before completion of the Placing		(ii) Immediately upon completion of the Placing	
	Number of Shares held	Approximate % of total Shares in issue	Number of Shares held	Approximate % of total Shares in issue
Golden Base Investment Limited	402,892,000	16.94	402,892,000	15.26
Ng Tit	500,000	0.02	500,000	0.02
Chin Yu	4,000,000	0.17	4,000,000	0.15
Ieong Chong Meng	527,381,500	22.18	527,381,500	19.97
Wang Minzhi	463,722,859	19.50	463,722,859	17.56
Annie Investment Co., Ltd.	1,700,000	0.07	1,700,000	0.06
Public Shareholders:				
The Placees	–	–	263,073,000	9.96
Other public Shareholders	977,625,704	41.12	977,625,704	37.02
Total	<u>2,377,822,063</u>	<u>100.00</u>	<u>2,640,895,063</u>	<u>100.00</u>

By order of the Board
China NT Pharma Group Company Limited
NG Tit
Chairman

Hong Kong, 21 September 2023

As at the date of this announcement, the executive Directors are Mr. Ng Tit and Ms. Chin Yu; the non-executive Director is Dr. Qian Wei; and the independent non-executive Directors are Mr. Yu Tze Shan Hailson, Dr. Zhao Yubiao, and Mr. Ng Ming Kwan.